What is OriGene Technologies?
Headquartered in Rockville, Maryland, OriGene Technologies operates as a comprehensive developer and manufacturer of genome-wide research tools. Since its inception in 1995, the company has built an extensive portfolio that includes cDNA clones, CRISPR/Cas9 genome editing products, and high-precision antibodies. By providing essential reagents and diagnostic kits to academic, pharmaceutical, and biotech institutions, OriGene facilitates advancements in cancer biomarker research, stem cell studies, and protein kinase analysis. Its market position is defined by a dual-focus on high-throughput research tools and specialized anatomic pathology products, enabling the company to serve as a vital partner for laboratories worldwide.
How much funding has OriGene Technologies raised?
OriGene Technologies has raised a total of $55.4M across 4 funding rounds:
Series B
$16M
Series C
$21.3M
Private Equity
$17.1M
Debt
$1M
Series B (2010): $16M with participation from Morningside Venture Investments, IDG-Accel, Zero2IPO Capital, and SBI Ven Capital
Series C (2013): $21.3M led by QiMing Venture Partners, Kleiner Perkins Caufield & Byers, and IDG-Accel
Private Equity (2015): $17.1M supported by Cathay Capital
Debt (2020): $1M featuring PPP
Key Investors in OriGene Technologies
Kleiner Perkins Caufield & Byers
A Menlo Park-based venture capital firm that invests in early and growth-stage technology and life-science companies, providing operational support from seed through IPO.
IDG-Accel
A global venture capital firm that partners with exceptional teams from the inception of their ideas through all phases of private company growth.
Cathay Capital
An international private equity firm specializing in cross-border investments that facilitate the expansion of middle-market enterprises across multiple continents.
What's next for OriGene Technologies?
With the backing of major enterprise-level funding, OriGene Technologies is well-positioned to accelerate its R&D initiatives and expand its global distribution footprint. The strategic focus moving forward likely involves deepening its integration into the clinical diagnostics market, where demand for high-quality IHC antibodies and molecular assay kits continues to rise. By leveraging its established infrastructure and the recent capital influx, the company is poised to enhance its gene synthesis and custom cloning services, further cementing its role as a primary provider for the next generation of genomic medicine and personalized healthcare research.
See full OriGene Technologies company page
